Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)

Hye Sook Han, Bum Jun Kim, Hee Jung Jee, Min Hee Ryu, Se Hoon Park, Sun Young Rha, Jong Gwang Kim, Woo Kyun Bae, Keun Wook Lee, Do Youn Oh, In Ho Kim, Sun Jin Sym, So Yeon Oh, Hyeong Su Kim, Ji Hye Byun, Dong Sook Kim, Young Ju Suh, Hyonggin An, Dae Young Zang

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Ramucirumab as monotherapy or in combination with paclitaxel is a second-line treatment option recommended for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. However, real-world data from large study cohorts focused on ramucirumab plus paclitaxel in gastric cancer are limited. Methods: The study population comprised all patients with gastric or GEJ cancer who received ramucirumab plus paclitaxel in South Korea between 1 May 2018 and 31 December 2018. We included patients with advanced gastric or GEJ adenocarcinoma and disease progression after first-line platinum and fluoropyrimidine-containing combination chemotherapy. Results: In total, 1063 patients were included in the present study. The objective response rate and disease control rate were 15.1% and 57.7%, respectively. The median progression-free survival was 4.03 months (95% confidence interval, 3.80–4.27) and the median overall survival was 10.03 months (95% confidence interval, 9.33–10.73). Grade 3 or higher treatment-related adverse events with incidence of ⩾5% were neutropenia (35.1%) and anemia (10.5%). Based on multivariable analysis, overall survival was negatively associated with Eastern Cooperative Oncology Group performance status ⩾2, weight loss ⩾10% in the previous 3 months, GEJ of primary tumor, poor or unknown histologic grade, number of metastatic sites ⩾3, presence of peritoneal metastasis, no prior gastrectomy, and time to second-line since first-line treatment <6 months. Conclusion: Our large-scale, nationwide, real-world data analysis of an unselected real-world population adds evidence for the efficacy and safety of second-line ramucirumab plus paclitaxel in patients with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Original languageEnglish
JournalTherapeutic Advances in Medical Oncology
Volume13
DOIs
Publication statusPublished - 2021

Bibliographical note

Funding Information:
This work was supported by the Korean Cancer Study Group and the Health Insurance Review & Assessment Service. The views expressed are those of the authors and not necessarily those of the Health Insurance Review & Assessment Service. We thank all investigators and their support staff who generously participated in this work.

Funding Information:
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by the Health Insurance Review & Assessment Service.

Publisher Copyright:
© The Author(s), 2021.

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint

Dive into the research topics of 'Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)'. Together they form a unique fingerprint.

Cite this